Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTEUS trial of ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone in high-risk proliferative diabetic retinopathy
2013-003640-23Phase 2Completed
- Sponsor
- AIBILI
- Start
- Nov 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by AIBILI. Primary endpoint: Regression of neovascularization. Started Nov 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2013-003640-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003640-23.